Innoveren Scientific Inc. · OTC:IVRN
Innoveren Scientific — Medovex — Investor Presentation (October 2016)
18 slides from Innoveren Scientific's investor presentation, Oct 11, 2016
Slide 1: October 2016
October 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement ZZ MeEpovex The information contained in this presentation has been prepared solely for informational purposes and is not an offer to buy or sell or a solicitation of an offer to buy or sell any securities or to participate in any investment strategy and may not be used oF reli
Slide 3: About Medovex
About Medovex ZZ Mepovex A company dedicated to “better sa : ENDURING RELIEF™ living through better medicine” Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for
Slide 4: Company Snapshot
Company Snapshot Strong management team and board of directors comprised of skilled surgeons, renowned physicians, a distinguished military general, and experienced business executives all with historic track records of success Highly disruptive flagship device the DenervexX™ System targeted at larg
Slide 5: Key Management & Board Members
Key Management & Board Members # Mepov EX ad isd Gd G2 Ga | iJ JoeSc y YS MEDIVATION 9 . Pe ny rc etn MiMedx —ENTRE{pp ~~ . A 79 smith&nephew BIOMIMETIC ANDREWS Ve ak AeigMed -O; DARA BiO Sciences MET 1S ‘dvancing Medical Discoveries —— spose. & _— golmonafolmen — stpyker
Slide 6: Management Bio's
Management Bio’s Jarret Gorlin serves as the Chief Executive Officer and a Director of the Company. He previously co-founded and served as President of Judicial Correction Services, Ine. which was named three consecutive yearsin a row as one of America’s fastest growing companies by Inc. Magazine. H
Slide 7: DenerveX System - The Problem
DenerveX™ System-The Problem Z Mepovex Facet joint syndrome (FJS) is a condition in which the joints in the back of the spine degenerate or are injured and subsequently cause pain.
Slide 8: DenerveX System - The Problem: Current Treatment Options
DenerveX™ System-The Problem Z Mepovex Current Treatment Options Spinal Injections Radio Frequency Ablation Treatment Effectiveness: Treatment Effectiveness: Temporary Temporary
Slide 9: DenerveX System - Our Solution (Proving the Concept)
DenerveX™ System-Our Solution (Proving the Concept) MEDOVEX + Using a two-step procedure of facet joint capsular tissue removal and RF Ablation we demonstrated positive outcomes via a study of 174 patients. « In conducting a three to six year follow up it was shown that 73% of the patients were stil
Slide 10: DenerveX System
DenerveX™ System { Mepovex DenervexX is an innovative and less invasive new treatment, unlike any on the market, designed for facet joint pain relief.
Slide 11: DenerveX System - Health Care Economics
DenerveX™ System- Health Care Economics (Over a3 year Period) 99 © "eres Temporary : Treatments blations/ Pulsed RF (2 times annually) * Cost- $9,750 + Spinal Fusion (1 time) Long Term Treatment ~< Cost: $108,985 r 7 iatest Sole » proprietary methods) _ a }
Slide 12: DenerveX Pro-40 Generator
DenerveX™ Pro-40 Generator Z Mepovex « Exclusively designed for the DenervexX system * Synchronization with the hand-held device for accurate therapy ¢ Safety features: ¢ Three Levels of Effect, based on patient BMI, designed to deliver precise therapy for each patient * 30-second timer for each use
Slide 13: All Inclusive, Ready-to-Use, Single-Use Kit
All Inclusive, Ready-to-Use, Single-Use Kit Portal Tube _‘ Tissue Stabilizer ‘i if MepoveX Dilator a Hand-Held 1 Device @Mecovex Portal Driver
Slide 14: Potential Market
« 10% of American adults Potential Market (Millions) have chronic back pain * 31% of chronic back pain can be attributed to the Facet Joints « This would equate to almost 9 million people currently suffering from Facet Joint Involvement in the U.S. a = United States =Europe =LatinAmerica #AsiaPacifi
Slide 15: EuroSpine 2016
EuroSpine 2016 Patrick Kullmann, President and COO for Medovex, stated, “Region jovex is well-positioned to drive surgeon adoption of our newinnovative Denervex™ System across Europe.
Slide 16: EU/Worldwide DenerveX Launch Strategy Markets
EU/Worldwide DenerveX Launch Strategy Markets Zz MEDOVEX Immediate product launch by country and distributorafter successful CE Mark approval in three phases: Pilot Launch (30-45 days): + Germany, (Aureus Medical, Munich) . England (Edge Medical, Manchester) Phase I (45-120 days) + Ireland (Edge Med
Slide 17: DenerveX Launch Materials
DenerveX-Launch Materials ZL MEDOVEX DENERVEX” DENERVEX” Enoumma RELIEF (Roveresas Aswan: Sonanvaneey Stet Fay. o proce wproas i dongs ene nr et tet ct po Finally, a procedural approach designed for the long-lasting relief of facet joint pain. Brochure & Reimbursement Patient Sales Pres. Guide/ lang
Slide 18: Investment Highlights
Investment Highlights MEDOVEX Medovex NASDAQ: MDVX + Founded by Steve Gorlin (Entremed, Medicis, Medivation, MiMedx) and Dr. JamesAndrews (world renowned orthopedic surgeon) + Experienced and proven management team and board ofdirectors + High insider ownership (38%) + Large highly opportunistic mar